Loading
c-Met overexpression is a stain, not a gene change: strong (3+) membrane staining in at least half of tumour cells. It selects telisotuzumab vedotin, an antibody-drug conjugate, in previously treated non-squamous lung cancer.
The VENTANA MET (SP44) RxDx Assay scores c-Met protein on tumour cell membranes and cytoplasm; the telisotuzumab vedotin (Emrelis, May 2025) label defines high c-Met overexpression as 50 percent or more of tumour cells with strong (3+) staining, as determined by an FDA-approved test, in locally advanced or metastatic non-squamous NSCLC after prior systemic therapy (LUMINOSITY). About a quarter of non-squamous, EGFR wild-type lung cancers meet the bar. Overexpression can occur without amplification or exon 14 skipping and the three readouts are scored separately.
In plain words · A receptor that is either mutated in some lung cancers or amplified as an escape route when other lung cancer drugs fail.
If the SP44 stain shows strong c-Met in at least half of your non-squamous lung cancer cells, telisotuzumab vedotin is on label after a first treatment has stopped working. This is a protein stain, so a sequencing report that says nothing about MET does not answer the question; ask whether the stain was done.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
50 percent or more of tumour cells showing strong (3+) membranous and/or cytoplasmic c-Met staining on the VENTANA MET (SP44) RxDx Assay.
“MET protein expression (>= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining 3+)”
FDA: List of FDA-Authorized Companion Diagnostic Devices| Threshold | Drug | Cancer | Regulator | Source |
|---|---|---|---|---|
| >= 50% of tumour cells with strong (3+) staining | Telisotuzumab vedotin | Non-small-cell lung cancer | FDA | label |
| Device | Maker | Indication and sample | Drug | PMA / 510(k) |
|---|---|---|---|---|
| VENTANA MET (SP44) RxDx Assay | Ventana Medical Systems (Roche Tissue Diagnostics) | Non-Small Cell Lung Cancer (NSCLC) - Tissue | Telisotuzumab vedotin | P240037 (05/14/2025) |
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
Shares MET exon 14 skipping mutation, MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, Telisotuzumab vedotin, MET.
Shares MET exon 14 skipping mutation, MET amplification (gene copy number), MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, MET.
Shares Telisotuzumab vedotin, MET, Non-small-cell lung cancer.
Shares Immunohistochemistry (IHC) and the tag biomarker.
Shares MET amplification (gene copy number), MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, Telisotuzumab vedotin, MET.
Shares Immunohistochemistry (IHC), Non-small-cell lung cancer and the tag biomarker.
Shares Immunohistochemistry (IHC), Non-small-cell lung cancer and the tag biomarker.
Shares Immunohistochemistry (IHC) and the tag biomarker.